Cidara Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy CDTX

*Your capital is at risk

$221.38

+0 (+0%)

At Close: Apr 07, 2026

Cidara Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -100.00. In total, the insiders bought 2.58M and sold 6.61M CDTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-100.00
● Buy	2.58M shares
● Sell	6.61M shares
6% Buy Activity Strong Negative Correlation
Sell Signal High Confidence Jan 07, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -100. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming sell-side pressure (6% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 07, 2026 Buy	Common Stock M-Exempt	Ra Capital Management, L.p.	Director	1 286 786 Value: $129
Jan 07, 2026 Sell	Common Stock D-Return	Ra Capital Management, L.p.	Director	4 652 309 Value: $1.03B
Jan 07, 2026 Sell	Stock Option (right to buy) D-Return	Ra Capital Management, L.p.	Director	5 079 Value: $108.2K
Jan 07, 2026 Sell	Stock Option (right to buy) D-Return	Ra Capital Management, L.p.	Director	22 200 Value: $591.0K
Jan 07, 2026 Buy	Pre-Funded Warrants (Right to Buy) M-Exempt	Ra Capital Management, L.p.	Director	1 286 786 Value: $129
Jan 07, 2026 Sell	Series A Preferred Stock D-Return	Ra Capital Management, L.p.	Director	89 956 Value: $0
Jan 07, 2026 Sell	Employee Stock Option (right to buy) D-Return	Davarpanah Nicole Negar Chief Medical Officer	Officer	30 000 Value: $646.2K
Jan 07, 2026 Sell	Employee Stock Option (right to buy) D-Return	Davarpanah Nicole Negar Chief Medical Officer	Officer	5 000 Value: $68.5K
Jan 07, 2026 Sell	Common Stock D-Return	Davarpanah Nicole Negar Chief Medical Officer	Officer	8 333 Value: $1.85M
Jan 07, 2026 Sell	Common Stock D-Return	Davarpanah Nicole Negar Chief Medical Officer	Officer	12 553 Value: $2.78M
Jan 07, 2026 Sell	Employee Stock Option (right to buy) D-Return	Ward Shane COO & Clo	C-Suite Officer	50 000 Value: $1.08M
Jan 07, 2026 Sell	Employee Stock Option (right to buy) D-Return	Ward Shane COO & Clo	C-Suite Officer	135 540 Value: $1.46M
Jan 07, 2026 Sell	Employee Stock Option (right to buy) D-Return	Ward Shane COO & Clo	C-Suite Officer	12 499 Value: $171.2K
Jan 07, 2026 Sell	Employee Stock Option (right to buy) D-Return	Ward Shane COO & Clo	C-Suite Officer	6 207 Value: $125.4K
Jan 07, 2026 Sell	Employee Stock Option (right to buy) D-Return	Ward Shane COO & Clo	C-Suite Officer	12 500 Value: $540.0K
Jan 07, 2026 Sell	Common Stock D-Return	Ward Shane COO & Clo	C-Suite Officer	25 083 Value: $5.56M
Jan 07, 2026 Sell	Employee Stock Option (right to buy) D-Return	Karbe Frank Chief Financial Officer	C-Suite Officer	115 000 Value: $2.36M
Jan 07, 2026 Sell	Employee Stock Option (right to buy) D-Return	Stein Jeffrey President & CEO	CEO / President	13 249 Value: $691.6K
Jan 07, 2026 Sell	Employee Stock Option (right to buy) D-Return	Stein Jeffrey President & CEO	CEO / President	11 749 Value: $939.9K
Jan 07, 2026 Sell	Stock Option (right to buy) D-Return	Burgess Daniel D Director	Director	2 125 Value: $49.7K
Jan 07, 2026 Sell	Stock Option (right to buy) D-Return	Burgess Daniel D Director	Director	1 400 Value: $14.8K
Jan 07, 2026 Sell	Stock Option (right to buy) D-Return	Burgess Daniel D Director	Director	875 Value: $33.6K
Jan 07, 2026 Sell	Stock Option (right to buy) D-Return	Burgess Daniel D Director	Director	875 Value: $69.5K
Jan 07, 2026 Sell	Stock Option (right to buy) D-Return	Burgess Daniel D Director	Director	550 Value: $17.6K
Jan 07, 2026 Sell	Stock Option (right to buy) D-Return	Burgess Daniel D Director	Director	550 Value: $58.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CIDARA THERAPEUTICS

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
FISV	0%	Nov 30
K KEEL	0%	Nov 30
D DFTX	0%	Nov 30
R RKLZ	0%	Nov 30
R RKTO	0%	Nov 30

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by